Clinical Trial Update: Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating imatinib in combination with the CXCR4 antagonist BL-8040 for improving molecular response in chronic myeloid leukemia has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BL-8040
• Imatinib (imatinib)

Snippet

Sponsor: Sheba Medical Center | Conditions: Chronic Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN